266 related articles for article (PubMed ID: 18945765)
1. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
2. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.
Modlich U; Navarro S; Zychlinski D; Maetzig T; Knoess S; Brugman MH; Schambach A; Charrier S; Galy A; Thrasher AJ; Bueren J; Baum C
Mol Ther; 2009 Nov; 17(11):1919-28. PubMed ID: 19672245
[TBL] [Abstract][Full Text] [Related]
3. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing.
Knight S; Zhang F; Mueller-Kuller U; Bokhoven M; Gupta A; Broughton T; Sha S; Antoniou MN; Brendel C; Grez M; Thrasher AJ; Collins M; Takeuchi Y
J Virol; 2012 Sep; 86(17):9088-95. PubMed ID: 22696657
[TBL] [Abstract][Full Text] [Related]
4. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Bohne J; Chandra S; Will E; Margison GP; Williams DA; Baum C
Mol Ther; 2006 Feb; 13(2):391-400. PubMed ID: 16226060
[TBL] [Abstract][Full Text] [Related]
5. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.
Knight S; Bokhoven M; Collins M; Takeuchi Y
J Virol; 2010 May; 84(9):4856-9. PubMed ID: 20181689
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
7. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
8. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity.
Suerth JD; Maetzig T; Brugman MH; Heinz N; Appelt JU; Kaufmann KB; Schmidt M; Grez M; Modlich U; Baum C; Schambach A
Mol Ther; 2012 May; 20(5):1022-32. PubMed ID: 22334016
[TBL] [Abstract][Full Text] [Related]
9. Retrovirus and lentivirus vector design and methods of cell conditioning.
Cooray S; Howe SJ; Thrasher AJ
Methods Enzymol; 2012; 507():29-57. PubMed ID: 22365768
[TBL] [Abstract][Full Text] [Related]
10. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
11. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.
Montini E; Cesana D; Schmidt M; Sanvito F; Bartholomae CC; Ranzani M; Benedicenti F; Sergi LS; Ambrosi A; Ponzoni M; Doglioni C; Di Serio C; von Kalle C; Naldini L
J Clin Invest; 2009 Apr; 119(4):964-75. PubMed ID: 19307726
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer.
Carmo M; Alves A; Rodrigues AF; Coroadinha AS; Carrondo MJ; Alves PM; Cruz PE
J Gene Med; 2009 Aug; 11(8):670-8. PubMed ID: 19507176
[TBL] [Abstract][Full Text] [Related]
13. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
Rethwilm A
Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
[TBL] [Abstract][Full Text] [Related]
14. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
15. Preventing and exploiting the oncogenic potential of integrating gene vectors.
Modlich U; Baum C
J Clin Invest; 2009 Apr; 119(4):755-8. PubMed ID: 19348042
[TBL] [Abstract][Full Text] [Related]
16. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
[TBL] [Abstract][Full Text] [Related]
17. The host range of gammaretroviruses and gammaretroviral vectors includes post-mitotic neural cells.
Liu XH; Xu W; Russ J; Eiden LE; Eiden MV
PLoS One; 2011 Mar; 6(3):e18072. PubMed ID: 21464894
[TBL] [Abstract][Full Text] [Related]
18. Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.
Biasco L; Rothe M; Schott JW; Schambach A
Hematol Oncol Clin North Am; 2017 Oct; 31(5):737-752. PubMed ID: 28895844
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential.
Ramezani A; Hawley TS; Hawley RG
Stem Cells; 2008 Dec; 26(12):3257-66. PubMed ID: 18787211
[TBL] [Abstract][Full Text] [Related]
20. Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient mice.
Balaggan KS; Duran Y; Georgiadis A; Thaung C; Barker SE; Buch PK; MacNeil A; Robbie S; Bainbridge JW; Smith AJ; Ali RR
Gene Ther; 2012 Feb; 19(2):182-8. PubMed ID: 22113317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
